ACE-031: The Myostatin Blocker That Was Stopped, and Why
ACE-031 added 3.3% lean mass from one dose, then its Duchenne trial was halted over nosebleeds and telangiectasias. What happened and what it teaches.
Peptide Therapy
Growth Hormones
6 articles on Growth Hormones by Dr. med. univ. Julian Douwes: ACE-031: The Myostatin Blocker That Was Stopped, and Why; and more.
01
02
Follistatin: Myostatin Blockade and the Injectable Gap
Follistatin blocks myostatin and activin. The human evidence is gene therapy in muscular dystrophy and myositis, not injected protein. Protocols and law.
03
IGF-1 LR3: Strong Pharmacology, Zero Human Trials
IGF-1 LR3 is an engineered IGF-1 analogue that evades binding proteins. What the animal and native-IGF-1 data show, the protocols used, and the real risks.
04
MGF (Mechano Growth Factor): Real Biology, Contested Peptide
MGF is the IGF-1Ec splice variant switched on by mechanical loading. What the muscle biology shows, why two pharma labs could not reproduce the peptide effect.
05
PEG-MGF: A Long-Acting Version of an Unproven Peptide
PEG-MGF is PEGylated mechano growth factor, built to fix MGF's short half-life. FDA found no human exposure data. What the evidence, protocols and law say.
06
Peptides for Muscle Growth: What the Evidence Actually Supports
Evidence-based review of peptides for muscle growth. GH secretagogues, BPC-157 for recovery, safety risks, and where the human evidence stops.
